Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2021-02-22 Regulatory Filings
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing for a Foreign Private Issuer to report material information that is required to be disclosed to shareholders in their home country or that is subject to home country regulation, or that is intended to be made public in their home country. The content is a press release announcing the allowance of a Chinese patent application, which is material information. Since Form 6-K is a general reporting requirement for foreign private issuers and doesn't fit neatly into the specific categories like 10-K (Annual Report), ER (Earnings Release), or DIV (Dividend Notice), it falls best under the general regulatory filing category, RNS (Regulatory Filings), which serves as a fallback for miscellaneous SEC filings that aren't explicitly covered by the other definitions. The document length (6501 chars) is substantial enough that it is the report itself, not just an announcement of a report, although it contains an announcement (Exhibit 99.1). However, the primary document structure is the Form 6-K wrapper, which is a regulatory filing.
2021-02-22 English
Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy
Report Publication Announcement Classification · 1% confidence The document is very short (1765 characters) and explicitly states, "Attached hereto is a report on*6k* *6K22022021_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general SEC filing for foreign private issuers, often used for material events). According to Rule 2, when a document is short and announces the attachment or publication of a report, it should be classified as a Report Publication Announcement (RPA). The presence of the Israel Securities Authority and Tel Aviv Stock Exchange context confirms it is a regulatory filing announcement.
2021-02-22 English
Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing for a Foreign Private Issuer to report material information that is made public in its home country or required to be filed with a foreign securities exchange. The content announces the partial exercise of an underwriter's option related to a previously announced offering, which is a material corporate/financing event. This type of filing, which reports material information outside of the regular periodic reports (like 10-K or IR), often falls under the general 'Regulatory Filings' category (RNS) or, if it relates specifically to financing, 'Capital/Financing Update' (CAP). Since the core event is the exercise of an option related to a stock offering, it strongly relates to capital structure changes. However, Form 6-K itself is a general reporting mechanism. Given the specific definitions, 'CAP' (Capital/Financing Update) is the most accurate description of the *content* (announcing proceeds from an offering), while 'RNS' (Regulatory Filings) is the most accurate description of the *form type* if the content were less specific. Since the content is clearly about capital raising/offering proceeds, CAP is a strong candidate. However, Form 6-K is a broad reporting vehicle. Looking at the provided codes, there is no specific code for Form 6-K. Form 6-K often contains press releases about financing, which could map to CAP, or general material news, which maps to RNS. Since the document is a formal SEC filing (Form 6-K) reporting a specific financial transaction (exercise of offering option), and it is not a full report (10-K, IR), nor a simple press release announcement (RPA), it fits best as a general Regulatory Filing (RNS) or a Capital Update (CAP). Given the explicit mention of the offering and proceeds, CAP is highly relevant. If the document were purely a press release, RNS might be better, but this is the official 6-K wrapper. I will classify it as CAP because the substance is financing, but acknowledge RNS as a close alternative for the filing mechanism itself. Given the options, CAP captures the substance better than the generic RNS.
2021-02-18 English
Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares
Report Publication Announcement Classification · 1% confidence The document is very short (1765 characters) and explicitly states, "Attached hereto is a report on *6k* *6k18022021_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general SEC filing for foreign private issuers, often used for immediate reports). According to Rule 2, when a document is short and announces the attachment or publication of a report, it should be classified as a Report Publication Announcement (RPA). The reference to the Israel Securities Authority and the date (18/02/2021) confirms it is a regulatory filing announcement, but RPA is more specific for this wrapper document type.
2021-02-18 English
Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Form 6-K" filed with the SEC by a Foreign Private Issuer. Form 6-K is used to report material information that the company is required to disclose to its home country's regulators or stock exchange, or that it makes public in its home country. The content is a press release announcing the issuance of a new U.S. patent for its Allocetra immunotherapy. This type of material, non-periodic disclosure, especially when filed on Form 6-K, typically falls under the general category of regulatory announcements or filings that don't fit the specific periodic reports (like 10-K or IR) or specific event disclosures (like DIV or DIRS). Reviewing the definitions: - It is not an Annual Report (10-K). - It is not a specific financial result announcement (ER). - It is not a management change (MANG). - It is not a dividend announcement (DIV). - It is not a proxy statement (DEF 14A/PSI). Since Form 6-K filings are used for various material events and this specific content (patent issuance announcement) is a regulatory disclosure that doesn't fit the more specific categories like 'Capital/Financing Update' (CAP) or 'Legal Proceedings Report' (LTR), the most appropriate fallback category for a general, material regulatory filing that isn't a standard periodic report is 'Regulatory Filings' (RNS).
2021-02-16 English
Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy
Report Publication Announcement Classification · 1% confidence The document is very short (1754 characters) and explicitly states, "Attached hereto is a report on *6-k* *6K16022021_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is an SEC filing for foreign private issuers, often used for material events). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). Since this is a regulatory filing announcement, RPA is the most appropriate specific category over the general RNS fallback.
2021-02-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.